Hodgkin's Lymphoma Prognosis

Hodgkin’s lymphoma is one of the most curable forms of cancer, with 1-year, 5-year and 10-year survival rates of around 90%, 85% and 80%, respectively.

Treatments for the condition have been developed and improved over the last few decades and the most recent trials of chemotherapy agents have led to the highest survival rates yet. In one European trial, patients with a favorable outlook had a 5-year survival rate of 98% and even among those with a more negative prognosis, the rate was 85%.

Several factors are taken into consideration when determining the prognosis for a patient with Hodgkin’s lymphoma. Some of these include:

  • Age
  • General health and ability to withstand chemotherapy and the potential side effects
  • Subtype of Hodgkin’s lymphoma
  • Stage of the cancer
  • How aggressive the cancer is

Studies have shown that a worse outcome can be predicted in the presence of the following factors:

  • Male gender
  • Age at diagnosis of 45 years or older
  • Mixed cellularity subtype
  • Lymphocyte depleted subtype
  • Stage IV disease
  • Lymphocyte count of less than 8%
  • Hemoglobin level below 10.5 g/dL
  • Albumin level below 4.0 g/dL
  • White blood cell count of 15,000/μl or more
  • A raised erythrocyte sedimentation rate
  • Large number of lymph node groups involved

Survival rates are usually calculated as set periods of time (such as 5 years or 10 years) for which a person lives after the cancer has been diagnosed. Although this gives a general idea of the outcomes associated with treatment, the actual outcome can still vary from person to person depending on several factors.

Survival usually depends on the stage at which the cancer is diagnosed and treatment is initiated. Overall, the five-year survival rate among people with Hodgkin’s lymphoma is 85% and most of these people will be cured of the condition. However, the treatment can cause long-term complications such as infertility and patients are also at an increased risk of developing another form of cancer in the future.

Further Reading

Last Updated: Jul 6, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, July 06). Hodgkin's Lymphoma Prognosis. News-Medical. Retrieved on July 21, 2024 from https://www.news-medical.net/health/Hodgkins-Lymphoma-Prognosis.aspx.

  • MLA

    Mandal, Ananya. "Hodgkin's Lymphoma Prognosis". News-Medical. 21 July 2024. <https://www.news-medical.net/health/Hodgkins-Lymphoma-Prognosis.aspx>.

  • Chicago

    Mandal, Ananya. "Hodgkin's Lymphoma Prognosis". News-Medical. https://www.news-medical.net/health/Hodgkins-Lymphoma-Prognosis.aspx. (accessed July 21, 2024).

  • Harvard

    Mandal, Ananya. 2023. Hodgkin's Lymphoma Prognosis. News-Medical, viewed 21 July 2024, https://www.news-medical.net/health/Hodgkins-Lymphoma-Prognosis.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.